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Abstract Neurodegenerative disorders of the aging
population affect over 5 million people in the US and
Europe alone. The common feature is the progressive
accumulation of misfolded proteins with the formation of
toxic oligomers. Alzheimer’s disease (AD) is characterized
by cognitive impairment, progressive degeneration of
neuronal populations in the neocortex and limbic system,
and formation of amyloid plaques and neuroﬁbrillary tan-
gles. Amyloid-b (Ab) is the product of proteolysis of
amyloid precursor protein (APP) by b and c-secretase
enzymes. The neurodegenerative process in AD initiates
with axonal and synaptic damage and is associated with
progressive accumulation of toxic Ab oligomers in the
intracellular and extracellular space. In addition, neurode-
generation in AD is associated with alterations in neuro-
genesis. Ab accumulation is the consequence of an altered
balance between protein synthesis, aggregation rate, and
clearance. Identiﬁcation of genetic mutations in APP
associated with familial forms of AD and gene polymor-
phisms associated with the more common sporadic variants
of AD has led to the development of transgenic (tg) and
knock out rodents as well as viral vector driven models of
AD. While APP tg murine models with mutations in the N-
and C-terminal ﬂanking regions of Ab are characterized by
increased Ab production with plaque formation, mutations
in the mid-segment of Ab result in increased formation of
oligomers, and mutations toward the C-terminus (E22Q)
segment results in amyloid angiopathy. Similar to AD, in
APP tg models bearing familial mutations, formation of Ab
oligomers results in defective plasticity in the perforant
pathway, selective neuronal degeneration, and alterations
in neurogenesis. Promising results have been obtained
utilizing APP tg models of AD to develop therapies
including the use of b- and c-secretase inhibitors, immu-
nization, and stimulating neurogenesis.
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Introduction
Alzheimer’s disease (AD) is the most common neurode-
generative disorder in the aging population. It is charac-
terized by the progressive and irreversible deafferentation
of the limbic system, association neocortex, and basal
forebrain (Perry et al. 1977; Hyman et al. 1984; Wilcock
et al. 1988; Hof et al. 1990; Palmer and Gershon 1990;
Masliah et al. 1993), accompanied by the formation of
neuritic amyloid plaques, amyloid angiopathy, neuroﬁ-
brillary tangles (NFTs), and neuropil threads (Terry et al.
1994). This neurodegenerative process is followed by
reactive astrogliosis (Dickson et al. 1988) and microglial
cell proliferation (Rogers et al. 1988; Masliah et al. 1991).
Loss of synapses (DeKosky and Scheff 1990; Masliah
2001; Scheff and Price 2001) and axonal pathology (Raff
et al. 2002) are probably key neuropathological features
leading to dementia in these neurodegenerative disorders.
In addition, recent evidence suggests that alterations in the
niches for neurogenesis in the adult brain might also
contribute to the neurodegenerative process (Haughey
et al. 2002; Tatebayashi et al. 2003; Dong et al. 2004;
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Donovan et al. 2006). The unique patterns of cognitive
impairment that characterize AD, in turn, depend on the
neural circuitry speciﬁcally affected (Hof and Morrison
1994), the extent of the synapto-dendritic damage, and the
speed with which the injury propagates (Terry et al. 1991;
DeKosky et al. 1996). Recent evidence supports the con-
tention that neuronal cell death might occur later in the
progression of neurodegeneration and that damage to the
synapto-dendritic apparatus might be one of the earliest
pathological alterations (Masliah and Terry 1993, 1994;
Masliah 1998, 2001; Honer 2003; Scheff and Price 2003).
This is accompanied by the abnormal accumulation of
neuronal proteins in the extracellular space (e.g., plaques,
cerebral amyloid angiopathy [CAA]) or in intracellular
compartments (e.g., tangles and Lewy bodies [LBs]).
Abnormal accumulation and misfolding (toxic conversion)
of these synaptic and cytoskeletal proteins are being
explored as key pathogenic events leading to neurodegen-
eration (Koo et al. 1999; Ramassamy et al. 1999; Ferrigno
and Silver 2000).
In AD, amyloid-b peptide 1–42 (Ab1–42), a proteolytic
product of amyloid precursor protein (APP) metabolism
(Fig. 1), accumulates in the neuronal endoplasmic reticu-
lum (ER) (Cuello 2005) and extracellularly (Selkoe et al.
1996; Trojanowski and Lee 2000; Walsh et al. 2000). The
primary pathogenic event triggering synaptic loss and
selective neuronal cell death in these disorders is not yet
completely clear (Masliah 2000, 2001), however, recent
studies suggest that nerve damage might result from the
conversion of normally non-toxic monomers to toxic
oligomers (Volles et al. 2001; Volles and Lansbury 2002;
Walsh and Selkoe 2004) (Fig. 2), whereas larger polymers
and ﬁbers that often constitute the plaques might not be as
toxic (Lansbury 1999; Walsh et al. 2002). An example of a
naturally occurring oligomer species is Ab*56, which has
been shown to promote age-dependent memory deﬁcits
(Lesne et al. 2006). Ab*56 and Ab trimers secreted by
cultured cells could share common synaptotoxic properties
(Selkoe 2008). Previous studies have shown that the Ab
dimers, trimers, and higher-order oligomers secreted by
cultured neurons inhibit LTP and damage spines (Klein
et al. 2001; Walsh and Selkoe 2004; Townsend et al. 2006;
Selkoe 2008). Additional studies have shown that Ab
dimers derived from human CSF disrupt synaptic plasticity
and inhibit hippocampal LTP in vivo (Klyubin et al. 2008).
Together, these studies indicate that Ab oligomers ranging
in size from 2 to 12 subunits might be responsible for the
Fig. 1 Schematic diagram of
APP processing and
accumulation of toxic Ab
species. b- and c-secretase
cleavage of APP results in the
production of Ab1–40 and
Ab1–42, which accumulates into
neurotoxic oligomers
Fig. 2 Schematic diagram of factors contributing to Ab oligomeri-
zation. Defective cellular processes can lead to the accumulation of
Ab dimers, trimers, and oligomers, which in turn contribute to
neurogenesis defects and synaptic damage
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123synaptic damage and memory deﬁcits associated with AD
(Lacor et al. 2007).
Thus, when developing transgenic (tg) models of AD it
is important to consider the following outcome features:
(1) targeting the selective neuronal populations in the
neocortex and limbic system involved in learning and
memory; (2) favoring production of high levels of Ab1–42
over Ab1–40; (3) promoting accumulation of Ab oligomers;
(4) inducing post-transcriptional modiﬁcations (e.g., pyro-
glutamate Ab); (5) evaluating abnormal accumulation of
intracellular Ab; (6) evaluating development of amyloid
plaques and CAA; (7) evaluating neurodegeneration with
synaptic loss, axonal damage, and defects in neurogenesis;
and (8) behavioral and electrophysiological impairments
that correspond to the pattern of neurodegeneration.
Experimental modeling of Alzheimer’s disease
Although dramatic progress has been made in under-
standing the pathogenesis of neurodegenerative condi-
tions of the aged population, such as AD, Parkinson’s
disease (PD), and Lewy body disease (LBD), most of
these disorders remain incurable. Because of the near
epidemic proportion in the aging population, these dis-
orders pose a serious challenge to the health care system.
Identiﬁcation of new targets and development of bio-
logical mouse models holds the promise of better
understanding their pathogenesis and discovering and
testing new treatments.
Experimental models of AD could mimic individual or
multiple alterations found in AD; however, to date not a
single model mimics all the alterations observed in AD.
The best model is probably the aged monkey (Price et al.
1994), however, because of the time and cost involved in
utilizing this model, most studies have been focused on
developing murine models. Most of the tg animal models
of AD are based on the targeted overexpression of single
or multiple mutant molecules associated with familial AD
(FAD) (Table 1, Fig. 3). Currently, mutations in three
genes have been described, namely APP, presenilin (PS)1,
and PS2 (Hutton and Hardy 1997; Cruts and Van
Broeckhoven 1998; Rocchi et al. 2003; Bertoli-Avella
et al. 2004; Pastor and Goate 2004). Other APP and PS tg
models have been developed in rats, drosophila, and
C. elegans, either using constitutively active or regulat-
able promoters, or viral vectors. The main focus of this
review will be dedicated to murine APP tg models and the
corresponding neurodegenerative pathology and altera-
tions in neurogenesis, however, it is important to
emphasize that this represents one aspect of the disease;
other components, such as NFT pathology will be
addressed by others.
Experimental APP transgenic murine models
of Alzheimer’s disease
In AD, APP mutations as well as mutations in PS1 and 2
and polymorphisms in apolipoprotein E (ApoE) have also
been linked with AD (Fig. 2) and as such are important
targets. Most efforts toward developing tg models have
been focused on overexpression of mutant APP (Table 1)
in combination with mutant PS1. A summary of the FAD
mutations reproduced in tg mouse models is presented in
Fig. 3. Previously developed tg animal models have shown
that it is possible to reproduce certain aspects of AD
pathology over a shorter period of time (Masliah et al.
1996; Games et al. 1997; Price et al. 2000). In this model,
the platelet-derived growth factor (b chain) (PDGF-b)
promoter drives an alternatively spliced human APP
(hAPP) minigene (PDAPP) encoding mutated (Indiana,
V717F) hAPP695, 751, and 770 (Games et al. 1995;
Rockenstein et al. 1995). This confers a high ratio of
mRNA encoding mutated hAPP versus wild-type mouse
APP (Rockenstein et al. 1995), which promotes develop-
ment of typical amyloid plaques, dystrophic neurites, loss
of presynaptic terminals, astrocytosis and microgliosis
(Games et al. 1995, 1997; Masliah et al. 1996).
Other models have expressed mutant hAPP under the
regulatory control of either the human or murine (m)Thy1
promoter (Andra et al. 1996; Sturchler-Pierrat et al. 1997;
Moechars et al. 1999; Bornemann and Staufenbiel 2000)o r
the prion protein (PrP) promoter (Hsiao et al. 1996;
Borchelt et al. 1997). Amyloid deposition begins at
12 months of age; however, co-expression of mutant PS1
accelerates amyloid deposition, beginning at 4 months of
age (Borchelt et al. 1996, 1997; Holcomb et al. 1998).
Another previously developed model, where hAPP is also
expressed under the control of the PrP promoter, displays
even earlier onset of amyloid deposition, starting at
3 months and progressing to mature plaques and neuritic
pathology from 5 months of age, accompanied by high
levels of Ab1–42 (Chishti et al. 2001). While the PrP pro-
moter has provided several models that mimic aspects of
FAD, other promoters targeting expression of APP to
neurons provide alternative models demonstrating pathol-
ogy that recapitulate similar and additional aspects of FAD.
In this regard, we have generated lines of tg mice
expressing hAPP751 cDNA containing the London (Lon,
V717I) and Swedish (Swe, K670N/M671L) mutations
under the regulatory control of the mThy1 gene (mThy1-
hAPP751) (Rockenstein et al. 2001; Fig. 4). While
expression of mutant hAPP under the PDGF-b promoter
results in the production of diffuse (and some mature)
plaques (Games et al. 1995; Mucke et al. 2000), tg
expression of mutant hAPP under the mThy1 (Andra et al.
1996) and PrP (Hsiao et al. 1996; Borchelt et al. 1997)
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123promoters favors the formation of mature plaques in the
hippocampus and neocortex. This suggests that the differ-
ential patterns of Ab deposition might be dependent on the
speciﬁc neuronal populations selected by the promoter,
levels of expression and topographical distribution of the
transgene, and levels of Ab1–40 and Ab1–42. Consistent with
this, in FAD and Down syndrome, production of high
levels of Ab1–42 results in early plaque formation (Citron
et al. 1997). This suggests that early age of onset and
plaque formation depends on high levels of Ab1–42 pro-
duction (Rockenstein et al. 2001). Finally, of considerable
interest and wide attention is the triple tg mouse model
developed by LaFerla et al. (2007) (3xTg-AD) that
involves overexpression of mutant APP (Swe) and Tau
(P301L) under the Thy1.2 promoter in homozygous mutant
PS1 (M146V) knockin mice. These mice develop neuro-
logical deﬁcits, amyloid deposition, and tangle-like
pathology in the hippocampus (Oddo et al. 2003a, b).
Models with accumulation of intracellular Ab have also
been developed. Among the most interesting ones is a rat tg
model that expresses Swe/Ind mutant hAPP751 (K670N/
M671L, V717F) alone or with mutant PS1 (M146L) under
the control of the PDGF-b promoter (Echeverria et al.
2004a, b). These animals are characterized by extensive
intracellular amyloid accumulation, CREB activation, and
tau pathology (Echeverria et al. 2004a, b). Other APP tg rat
models express mutant hAPP695 (K670N/M671L) under
the control of the ubiquitin-C (UbC) promoter, which
shows a similar ubiquitous expression pattern as the human
APP promoter (Folkesson et al. 2007); (Agca et al. 2008).
These animals have been shown to develop extracellular
amyloid deposits at 15–18 months. A third rat line carrying
both mutant APP (K670N/M671L) and a human PS1
transgene with the FAD M146V mutation under the control
of the rat synapsin 1 promoter develops plaques at
7 months of age (Flood et al. 2009). While these models
show promising results recapitulating the intracellular
accumulation of Ab that is observed in AD patients, more
detailed neuropathological examination is necessary to
fully characterize these models. Interestingly, the 3xTg-AD
model described earlier has also been shown to accumulate
intraneuronal Ab, and more recent studies have focused on
this as a mouse model of intracellular Ab deposition. In
these animals, accumulation of intraneuronal Ab leads to
progressive degeneration and death of neurons in the brains
of tg mice (LaFerla et al. 2007).
Remarkably, post-transcriptionally modiﬁed Ab also
accumulates in substantial quantities intraneuronally
(Fig. 5). In particular, pyroglutamate Ab3–42 triggers a
lethal phenotype with neurodegeneration in a mouse model
that expresses Ab3–42 peptides under the control of the
Thy1 promoter (TBA2 tg) (Wirths et al. 2009). This model
expresses Ab with N-terminal glutamine (Ab3Q-42) as a
fusion protein with the murine thyrotropin-releasing hor-
mone (mTRH), for transport via the secretory pathway
(Cynis et al. 2006). The levels of converted Ab (3(pE)-42)
in TBA2 mice are comparable to the APP/PS1 knockin
mouse model (Casas et al. 2004), with extensive neuron
loss and associated behavioral deﬁcits (Wirths et al. 2009).
Eight weeks after birth, TBA2 mice develop neurological
Fig. 3 Diagram showing
common mutations in the APP
gene that are utilized in the
generation of animal models of
AD. Mutations in the N- and
C-terminal domains of APP
result in the accumulation of
intracellular and/or extracellular
Ab species, while mutations in
the Ab region lead to the
development of amyloid
angiopathy. Swe Swedish
mutation, Lon London mutation,
Ind Indiana mutation,
Arc Arctic mutation,
TM transmembrane domain
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123impairments together with abundant loss of Purkinje cells
(Wirths et al. 2009). Although the TBA2 model lacks
important AD-typical neuropathological features like tan-
gles and hippocampal degeneration, it clearly demonstrates
that intraneuronal Ab (3(pE)-42) is neurotoxic in vivo
(Wirths et al. 2009).
To further understand the mechanisms involved in Ab
deposition and clearance, a unique model of neuronal APP
expression has been developed that expresses mutant (Swe/
Ind) hAPP695 under the control of a tetracycline-sensitive
promoter (Jankowsky et al. 2005). This approach allows
the instantaneous abolition (95%) of hAPP expression upon
treatment with doxycycline. Animals were treated with
antibiotic after plaques were already formed and in this
model, very little new hAPP—and subsequently, Ab—is
produced after antibiotic treatment, so the natural rate of
Ab clearance can be assessed. Notably, even after
12 months of suppression of APP production, amyloid
deposits in the brains of treated mice remained abundant
(Jankowsky et al. 2005). This indicates that, once formed,
amyloid plaques are highly resistant to dissolution in the
brain, and further suggests that therapeutic approaches
based solely on reducing amyloid production may not be
effective, and may need to be combined with clearance-
based treatments.
While most animal models of AD involve ectopic
expression or overexpression of FAD-related genes, some
pathological features of AD have been recapitulated in
mutant and knockin animals in which FAD-causing
mutations are targeted into their endogenous genes. One
advantage to gene-targeted and knockin models is that
developmental and tissue-speciﬁc expression patterns of
human Ab are relatively preserved because the gene
encoding the mutant precursor protein remains in its nor-
mal chromosomal location. One of the ﬁrst models to
express mutant APP in its endogenous location in the
Fig. 4 Characterization of cognitive and neuropathological altera-
tions in the brains of mThy1-hAPP tg mice. a Structure of mutant
hAPP transgene under the control of the mThy-1 promoter. b Memory
portion of the water maze behavioral test where the platform was
removed (Probe test) to evaluate the number of entrances into the
target quadrant where the platform was previously located
(# Entrances), the number of times the animal passed over the
location, where the platform was (# Passes), and time spent (Time)
swimming in the target quadrant where the platform was previously
located. APP tg mice exhibited reduced performance compared to
non-tg controls in all three measures of memory retention in this
behavioral test. c Ab-immunoreactive deposits in the cortex of
an APP tg mouse. Scale bar 50 lm. d Reduced synaptophysin
immunoreactivity in the brain of an APP tg mouse. Scale bar 0.2 mm.
e Degeneration of the MAP2-immunoreactive dendritic arbor in
the cortex of an APP tg mouse. Scale bar 10 lm. f hAPP
immunoreactivity in the dentate gyrus (DG) of an APP tg mouse.
Scale bar 1 mm (left panel), 20 lm (right panel). *p\0.05
compared to non-tg controls by Student’s t-test (n = 4 mice per
group)
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123mouse genome used site-speciﬁc mutagenesis to transform
murine APP into ‘‘humanized’’ APP bearing the Swe
mutation (K670N/M671L) (Reaume et al. 1996). In this
model, amyloidogenic processing was somewhat enhanced
and measurable increases in Ab production were detected
(Siman et al. 2000), however, the effects were not as robust
as in APP tg models. Interestingly, in the gene-targeted
mutant APP animals, the pathological process is markedly
enhanced upon introduction of a PS1 P264L knockin
mutation in these mutant APP animals, characterized by a
large increase in Ab1–42 levels and an acceleration of age-
dependent onset of amyloid pathology (Siman et al. 2000).
It is still controversial which Ab species is responsible
for the neurodegenerative process in AD. While most
recent studies support a role for small oligomers (dimers,
trimers, up to dodecamers) (Walsh and Selkoe 2004; Glabe
2005; Glabe and Kayed 2006), others emphasize an
important role for the accumulation of intracellular Ab and
for post-transcriptional modiﬁcations, such as pyrogluta-
mate changes (Cynis et al. 2008; Schilling et al. 2008).
Models reproducing the formation of Ab oligomers include
those expressing APP bearing the Arctic mutation (E22G)
under the control of the PDGF-b promoter (Cheng et al.
2004). This mutation is highly ﬁbrillogenic in vivo, and
these mice rapidly develop extensive plaque formation
(Cheng et al. 2004). Mutations that increase oligomers and
protoﬁbril formation include the E22G (Arctic), E22K
(Italian), E22Q (Dutch), and the D23N (Iowa) amino acid
substitutions (Demeester et al. 2001; Lashuel et al. 2003;
Betts et al. 2008; Fig. 3). Interestingly, all of these muta-
tions are located within the Ab-containing sequence of
APP, and in addition to the apparent oligomer-promoting
effect of these mutations, it has been proposed that the
pathogenic effect may also be related to a resistance in
proteolysis of Ab (Tsubuki et al. 2003). In support of this
possibility, another familial APP mutation, A21G (Flem-
ish), exhibits a signiﬁcantly reduced rate of proteolysis by
the Ab-degrading enzyme Neprilysin (Betts et al. 2008).
Most emphasis has been placed on the amyloid depo-
sition in the intracellular compartment and in the plaques.
However, patients with AD also develop amyloid deposi-
tion around blood vessels, a process that ultimately leads to
a condition known as cerebral amyloid angiopathy (CAA).
This can cause vascular fragility and hemorrhages
(reviewed in Pezzini et al. (2009)), and it is important to
note that therapeutic anti-Ab vaccination strategies may
increase susceptibility to developing CAA (Boche et al.
2008). Patients who have hereditary cerebral hemorrhage
with amyloidosis-Dutch type (HCHWA-D) generate both
wild-type Ab and E22Q-mutant Ab (Ab Dutch) (van
Duinen et al. 1987; Levy et al. 1990). The brains of
patients with HCHWA-D show CAA with very little
parenchymal amyloid deposition (Herzig et al. 2006). To
date, there are several mouse models that deposit amyloid
in the blood vessels, including some models more widely
used to study parenchymal Ab accumulation, such as the
Tg2576 mouse (Hsiao et al. 1996; Frackowiak et al. 2003).
The only mouse model that develops signiﬁcant cerebro-
vascular amyloid with virtually no parenchymal amyloid is
the APPDutch mouse, which overexpresses hAPP751
bearing the E693Q (E22Q in Ab) mutation under the
control of the Thy1 promoter (Herzig et al. 2004). More
recently, the same group has also developed a new model
of CAA by crossing the APPDutch mutant mice with
Fig. 5 Increased intracellular
pyroglutamate-Ab
immunoreactivity and synaptic
deterioration in mThy1-hAPP tg
mice. a–c Sections from the
brains of non-tg and APP tg
mice were immunolabeled with
an antibody against
pyroglutamate Ab3–42 and
developed with DAB. Increased
intraneuronal immunoreactivity
was detected in the cortex of
APP tg mice compared to
non-tg controls. Scale bar
20 lm. d–f Reduced
synaptophysin (SY38)
immunoreactivity in the
neuropil of APP tg mice
compared to non-tg controls.
Scale bar 20 lm. *p\0.05
compared to non-tg controls by
Student’s t-test (n = 4 mice
per group)
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123APP23 mice that express mutant hAPP751 (Swe) under the
control of the Thy1 promoter (Herzig et al. 2009). While
the classical APP23 mice display extracellular Ab plaques,
double-tg APP23/APPDutch mice co-deposited Ab Dutch
(mainly Ab Dutch1-40) and wild-type Ab at twofold levels
in the vasculature, with reduced parenchymal deposition
(Herzig et al. 2009). Hemorrhages were also signiﬁcantly
increased in the double-tg mice. These studies suggest that
Ab Dutch1-40 increases vascular deposits and reduces
parenchymal amyloidosis similar to HCHWA-D patients.
For a comprehensive review of these and additional tg
models of neurodegenerative disease, please visit the
Alzheimer’s forum website at: http://www.alzforum.org/
res/com/tra.
Alterations in APP processing, synaptic plasticity,
and neurogenesis in APP tg models
The most signiﬁcant correlate to the severity of the cog-
nitive impairment in AD is the loss of synapses in the
frontal cortex and limbic system (DeKosky and Scheff
1990; Terry et al. 1991; Masliah and Terry 1994; DeKosky
et al. 1996; Figs. 2, 4). The pathogenic process in AD
involves alterations in synaptic plasticity that include
changes in formation of synaptic contacts, changes in spine
morphology, and abnormal area of synaptic contact (Scheff
and Price 2003). However, other cellular mechanisms
necessary to maintain synaptic plasticity might also be
affected in AD (Cotman et al. 1993; Masliah 2000;
Masliah et al. 2001). Recent studies indicate that neuro-
genesis in the mature brain plays an important role main-
taining synaptic plasticity and memory formation in the
hippocampus (van Praag et al. 2002). In the adult nervous
system, motor activity and environmental enrichment (EE)
have been shown to stimulate neurogenesis in the hippo-
campal dentate gyrus (DG) (Gage et al. 1998; van Praag
et al. 2002). Physiological neurogenesis in the adult brain
is regulated by numerous cell extrinsic and intrinsic factors,
including local cytokine/chemokine signals and intracel-
lular signal transduction (Johnson et al. 2009). In this
context, recent studies have shown that, among other
pathways, the Notch (Breunig et al. 2007; Crews et al.
2008), cyclin-dependent kinase-5 (CDK5) (Jessberger
et al. 2008; Lagace et al. 2008), and wnt/bone morphoge-
netic protein (BMP) (Lim et al. 2000; Lie et al. 2005)
cascades are involved in regulating adult neurogenesis.
Interestingly, studies of human brains (Tatebayashi et al.
2003) and tg animal models have demonstrated signiﬁcant
alterations in the process of adult neurogenesis in the
hippocampus in AD (Dong et al. 2004; Jin et al. 2004;
Wen et al. 2004; Chevallier et al. 2005; Donovan et al.
2006). The deﬁcient neurogenesis in the subgranular zone
(SGZ) of the DG found in our APP tg mice (Rockenstein
et al. 2007; Fig. 6) is consistent with studies of other lines
of APP tg mice and other models of AD that have
shown decreased markers of neurogenesis, such as bromo-
deoxyuridine (BrdU)?, and doublecortin (DCX)? cells,
with an increase in the expression of markers of apoptosis
(Feng et al. 2001; Haughey et al. 2002; Dong et al. 2004;
Wang et al. 2004).
A different study reported increased neurogenesis in the
PDAPP model (Jin et al. 2004). Another recent study
showed that in 5-month-old APP23 tg mice prior to
amyloid deposition, there was no robust difference in
neurogenesis relative to wild-type control mice, but
25-month-old amyloid-depositing APP23 mice showed
signiﬁcant increases in neurogenesis compared to controls
(Ermini et al. 2008). In contrast, 8-month-old amyloid-
depositing APP/PS1 tg mice revealed decreases in neuro-
genesis compared to controls. Furthermore, 8-month-old
nestin-GFP 9 APP/PS1 mice exhibited decreases in qui-
escent nestin-positive astrocyte-like stem cells, while
transient amplifying progenitor cells did not change in
number (Ermini et al. 2008). Strikingly, both astrocyte-like
and transient-amplifying progenitor cells revealed an
aberrant morphologic reaction toward congophilic amyloid
deposits. A similar reaction toward the amyloid was no
longer observed in doublecortin-positive immature neurons
(Ermini et al. 2008). These results provide evidence for a
disruption to neuronal progenitor cells (NPCs) in an amy-
loidogenic environment and support ﬁndings that neuro-
genesis is differentially affected among various tg mouse
models of AD, probably due to variations in promoter cell
type speciﬁcity, expression levels, and other factors. A
more comprehensive analysis of neurogenesis in APP tg
mice showed that while in the molecular layer (ML) of the
DG there is an increased number of NPC, in the SGZ
markers of neurogenesis are decreased, indicating that in
PDAPP animals there is altered migration and increased
apoptosis of NPC that contributes to the deﬁcits in neuro-
genesis (Donovan et al. 2006).
The molecular mechanisms of aberrant neurogenesis in
AD are unclear, however, several signaling pathways that
control physiological adult neurogenesis are known to be
dysregulated in AD. For example, CDK5 is hyperactivated
in AD by Ab peptide-mediated calcium inﬂux (Lee et al.
2000). In mature neurons, this contributes to neurodegen-
eration by promoting aberrant phosphorylation of down-
stream targets of CDK5 such as tau (Ahlijanian et al.
2000), however, the direct effects on NPCs are unknown. It
is possible that kinases, such as CDK5 that are disturbed in
mature neurons in AD may also play a role in the mech-
anisms of disrupted neurogenesis in the adult AD brain.
While a considerable body of work is currently emerging
on neurogenic alterations associated with the pathogenesis
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123of AD, it is important to keep the role of neurogenesis in
perspective given the relatively limited number of brain
regions that are neurogenic. It is an exciting prospect that
new neurons from progenitor cells in the hippocampus
could replace cells damaged during the pathogenesis of AD.
However, the extent to which progenitor cells might inte-
grate into already-established neural circuitry is unclear,
and the problem of re-establishing long inter-regional
connections is considerable. Furthermore, taking into
account the distribution of AD pathology among various
non-neurogenic brain regions, such as the entorhinal cortex
and neocortex, it is possible that neurogenesis may not be an
ideal target for repairing global neuronal damage in the
brain. However, given the critical role of the hippocampus
in the processes of learning and memory, and the recent
studies showing that neurogenesis plays an important part in
these functions (van Praag et al. 2002), it is possible that
modulation of neurogenesis in this area might have thera-
peutic potential. Moreover, it is important to consider the
interconnected circuitry that characterizes the brain’s
architecture. Although AD pathology in the hippocampus
primarily affects the non-neurogenic pyramidal cell layers,
the granular cells extend processes into the pyramidal
layers, and additionally affect the connectivity of the
entorhinal cortex via the perforant pathway. Taken together,
much further work will be necessary to fully understand the
role of neurogenesis in the pathogenesis of AD and the
therapeutic potentialof harnessing the regenerative capacity
of progenitor cells.
Alterations in synaptic plasticity in AD might involve
not only direct damage to the synapses but also interference
with adult neurogenesis (Fig. 2). The mechanisms of syn-
aptic pathology in AD are the subject of intense investi-
gation. Studies of experimental models of AD and in
human brain support the notion that aggregation of Ab,
resulting in the formation of toxic oligomers rather than
ﬁbrils, might be ultimately responsible for the synaptic
damage that leads to cognitive dysfunction in patients with
AD (Walsh and Selkoe 2004; Glabe 2005; Glabe and
Kayed 2006; Fig. 1). Supporting this notion, it has been
shown that Ab oligomers reduce synaptic transmission and
dendritic spine movement (Lacor et al. 2004; Moolman
et al. 2004; Walsh and Selkoe 2004), and interfere with
axoplasmic ﬂow and activate signaling pathways that
might lead to synaptic dysfunction, tau hyperphosphory-
lation, and cell death. Moreover, a dodecameric Ab com-
plex denominated *56 has been recently characterized
(Lesne et al. 2006) in brains from APP tg mice and shown
Fig. 6 Reduced markers of
neurogenesis and increased
apoptosis in the hippocampus of
APP tg mice. a–c Reduced
BrdU immunoreactivity in the
hippocampal dentate gyrus of
APP tg mice treated with BrdU
compared to non-tg controls
treated with BrdU. d–e Reduced
doublecortin (DCX)
immunoreactivity in the
hippocampal dentate gyrus
of APP tg mice compared to
non-tg controls. g–i Reduced
proliferating cell nuclear
antigen (PCNA)
immunoreactivity in the
hippocampal dentate gyrus
of APP tg mice compared to
non-tg controls. j–l Increased
TUNEL-positive cells in the
hippocampal dentate gyrus of
APP tg mice compared to non-
tg controls. Scale bar 50 lm for
all panels. *p\0.05 compared
to non-tg controls by Student’s
t-test (n = 4 mice per group)
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123to contribute to the behavioral alterations in these animals.
The differential effects of this and other toxic oligomeric
species of Ab in mature and developing neurons and syn-
apses awaits further investigation.
The accumulation of Ab in the CNS and the formation
of toxic oligomers most likely depend on the rate of Ab
aggregation, synthesis, and clearance (Fig. 7). Although
most effort has been concentrated at elucidating the
mechanisms of Ab production and aggregation (Luo et al.
1999; Sinha et al. 1999; Vassar et al. 1999; Selkoe 2000;
Cai et al. 2001), less is known about the mechanisms of Ab
clearance. As previously discussed in the section on tg
models, the conditional APP tg model showed that
enhancing clearance of Ab may actually be more critical
than preventing its production when considering potential
therapies. This is also important because while most
familial forms of AD might result from mutations that
affect the rate of Ab synthesis and aggregation, sporadic
AD might be the result of alterations in Ab clearance
(Fig. 7). Pathways involved in Ab clearance include
LDLR-related protein (LRP) ligands, such as apolipopro-
tein E (ApoE) (Holtzman et al. 1995, 1999), lysosomal
degradation (Nixon et al. 1992, 2005) and cleavage by
proteolytic enzymes, such as Neprilysin, insulin-degrading
enzyme (IDE), endothelin-converting enzyme (ECE),
angiotensin converting enzyme (ACE), and matrix
metalloproteinase-9 (MMP9) (Iwata et al. 2000, 2001;
Selkoe 2001; Carson and Turner 2002; Leissring et al.
2003; Marr et al. 2004; Eckman and Eckman 2005; Saito
et al. 2005; Fig. 7).
Functional correlations to the structural pathology
in APP tg mice
The relationship among the patterns of Ab production,
amyloid deposition, neurodegeneration, and behavioral
deﬁcits in the tg models of AD is complex. One important
ﬁnding common to several of these APP tg models is that
there is no obvious neuronal dropout in early stages of
pathogenesis (Irizarry et al. 1997a, b). In fact, the earliest
neuronal pathology before amyloid deposition is the loss of
synapses and dendrites in the limbic system and neocortex
(Hsia et al. 1999; Mucke et al. 2000). This is accompanied
by neurophysiological deﬁcits and alterations in long-term
potentiation (LTP) and ﬁeld potential (Chapman et al.
1999; Hsia et al. 1999). Since the synaptic damage in these
mice correlates better with the levels of soluble Ab1–42 than
with plaques, it has been proposed that neurodegeneration
might be associated more with the neurotoxic effects of Ab
oligomers than with ﬁbrillar amyloid (Mucke et al. 2000).
In agreement with this possibility, studies of brain slices
have shown that Ab oligomers rather than ﬁbrillar amyloid
are toxic to synapses and depress LTP, leading to cognitive
impairment (Walsh et al. 2002).
Other recently developed models have also focused on
deﬁning the effects of APP and its products on functional
markers, including behavioral performance and LTP.
These studies have shown that overexpression of the
C-terminal APP fragment C100 under the control of neu-
roﬁlament (NF) promoter results in amyloid-like produc-
tion and electrophysiological alterations (Nalbantoglu et al.
1997). Although these, as well as the other APP tg animal
models, have been shown to be of signiﬁcant interest, the
basic principle for their success rests in the ability to
overexpress high levels of mutant APP, which is in a way
rather non-physiological event. With the exception of
Down syndrome, in sporadic AD there is no evidence for
upregulation of APP expression but rather a shift in the
ratio between APP770 and 751 to APP695. In this regard, a
previous study (van Leeuwen et al. 1998) has shown frame
shift mutations in APP and ubiquitin genes are present in
some AD patients. It is conceivable that future tg models
might utilize this mechanism in an attempt to reﬂect the
more common sporadic forms of the disease.
Conclusions
In summary, a number of known mutations in the APP gene
associated with familial forms of amyloid disorders have
made it possible to recapitulate several features of amyloid
pathology in the brains of tg animal models. While other
genes, such as PS1 and tau have been manipulated alone or
in combination with APP mutations, a large portion of the
current literature describing the AD-like neurodegenerative
phenotypes in animal models has been based on animal
models expressing high levels of mutant APP. While APP
tg murine models with mutations in the N- and C-terminal
ﬂanking regions of Ab are characterized by increased Ab
production with plaque formation, mutations in the mid-
segment of Ab result in increased formation of oligomers,
and mutations toward the C-terminus (E22Q) segment
results in amyloid angiopathy. Several lines of evidence
Fig. 7 Schematic diagram showing several factors involved in the
regulation of Ab accumulation into oligomers, including production,
aggregation, and clearance
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123suggest that formation of Ab oligomers reduces neuro-
plasticity and contributes to neuronal degeneration and
alterations in neurogenesis. Speciﬁcally targeting these
toxic oligomeric species of Ab with b- and c-secretase
inhibitors, immunization, and neurogenesis-stimulating
therapies may provide individual or combination treatments
that ameliorate multiple features of AD pathology.
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